Modified Pup Molecules for Dop Inhibitor Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis are inefficient due to the unique properties of Mycobacterium tuberculosis, including a slow-dividing cell wall and antibiotic-resistant strains, leading to severe side effects and the need for new drug targets that are specific to the bacteria and not present in humans.
Innovation Solution
Development of modified prokaryotic ubiquitin-like protein (Pup) molecules with fluorescent moieties attached via covalent linkages, used in screening methods to identify modulators of Pup activity, which can inhibit the deamidase activity of Dop, a key enzyme in the Pup-proteasome pathway essential for Mtb virulence, thereby treating tuberculosis and leprosy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotics are used to treat Mtb, then bacterial infection can be addressed, but treatment efficiency is low due to slow-dividing cell wall and antibiotic-resistant strains
Solution Approach 1:
The patent changes the target parameter from conventional antibiotic targets to the Pup-proteasome pathway components (Pup, Dop, Mpa, PafA). This parameter change enables inhibition of Mtb protein degradation machinery, which is essential for bacterial survival and virulence, thereby overcoming antibiotic resistance and improving treatment efficiency
Solution Approach 2:
The patent uses modified Pup molecules with fluorescent moieties as intermediaries to screen and identify modulators of Pup activity. These fluorescently labeled Pup molecules serve as mediators between the screening system and the target enzymes (Dop, PafA), enabling detection and selection of effective inhibitors
2Reliability
If combination antibiotic therapy is used to treat tuberculosis, then bacterial infection can be addressed, but severe side effects occur
Solution Approach 1:
The patent targets specific bacterial components (Pup, Dop, Mpa, PafA) that are unique to Mycobacterium tuberculosis and not present in human cells. This localized targeting ensures that the therapeutic action is confined to the bacterial pathogen, sparing human cells from damage and thereby reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent shifts the therapeutic target from conventional antibiotics to the Pup-proteasome pathway, which is essential for Mtb virulence and survival. This parameter change enables selective inhibition of bacterial protein degradation without affecting human proteasome function, reducing toxicity while maintaining effectiveness
3Adaptability or versatility
If new drug targets are developed specific to Mtb, then treatment specificity can be improved, but device complexity increases due to need for modified Pup molecules and screening methods
Solution Approach 1:
The patent employs fluorescently modified Pup molecules as intermediaries that simplify the screening process. These fluorescent tags enable direct detection of Pup activity and modulator binding through fluorescence signals, converting a complex biochemical interaction into a simple, measurable optical readout that reduces screening complexity
Solution Approach 2:
The patent replaces complex biochemical assays with fluorescence-based detection methods. By using fluorescent moieties attached to Pup molecules, the patent substitutes traditional complex measurement techniques with simpler fluorescence reading, thereby reducing the complexity of the screening method while maintaining high specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Pup molecules enable the identification of compounds that effectively inhibit Dop activity, potentially leading to new therapeutic agents that are specific to Mtb, reducing side effects and overcoming antibiotic resistance.
Implementation Method 1
wherein the modification is a fluorescent moiety
Data Source
AI summary
Methods for making and using substrates of deamidase of prokaryotic ubiquitin-like protein (Dop) are described herein. More particularly, modified prokaryotic ubiquitin-like protein (Pup) and functional fragments thereof that serve as exemplary Dop substrates are described and encompassed herein. Screening methods to identify modulators of Dop and Pup activity and use of modulators identified thereby are also described. Methods of using modulators that are identified as inhibitors of Dop and Pup activity for treating diseases/conditions associated with Mycobacterium tuberculosis (Mtb) infection, such as tuberculosis and leprosy, are also envisioned.